Skip to main content

Table 1 Tamoxifen-resistant cells develop individual as well as common drug sensitivities and co-resistances. Sensitizing and desensitizing drugs, drug target classes, specific target genes and as well as affected cell lines are listed

From: Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

Sensitivity towards

Drug target class

Specific target gene

Observed in cell line

Navitoclax, Obatoclax

BCL-family

BCL2L1

T-47D Tam1

BAD

RAF265, Ponatinib

RAF-family

RAF1

T-47D Tam1

Dasatinib, KX2-391

SRC/ABL

ABL1

T-47D Tam1 & Tam2

SRC

VX-11E

MAPK1

MAPK1

T-47D Tam2, BT-474 Tam2, ZR-75-1 Tam2

Gefitinib, Ibrutinib, Neratinib, Nintedanib

HER2/EGFR

ERBB2

BT-474 Tam1 & Tam2

ERBB4

ERBB3

Vinblastine

Tubulins

TUBA1A

T-47D Tam2

TUBA4A

TUBA1C

TUBB6

PF-3845

FAAH

FAAH

ZR-75-1 Tam2

Bortezomib

PSMB-family

PSMB5

ZR-75-1 Tam2

Resistance towards

Drug target class

Specific target gene

Observed in cell line

YM155

BIRC5

BIRC5

T-47D Tam1 & Tam2, MCF-7 Tam1, BT-474 & Tam2

Quisinostat, Panobinostat

HDACs

HDAC1

T-47D Tam2, MCF-7 Tam1

HDAC6

Docetaxel, Paclitaxel

Tubulins

TUBA1C

BT-474 Tam2

TUBB2A

TUBB3

TUBB

TUBB4B

TUBB6

Temsirolimus, Everolimus, Ridaforolimus, INK128, Sirolimus, AZD8055, Dactolisib

mTOR

mTOR

MCF-7 Tam1